EU Advisory Panel Clears Sanofi’s Jevtana But Wants to Review Multaq’s Liver Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis' cabazitaxel receives a positive opinion from the EU's scientific advisory committee, but the benefit/risk balance of the French company's anti-arrhythmic, Multaq, needs to be reviewed.